Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company focused on minimally invasive surgical technologies for sacropelvic disorders, including sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, spinopelvic and sacropelvic fixation, and pelvic trauma. This news page aggregates company press releases and market updates related to SIBN stock and SI-BONE’s sacropelvic platform.
Investors following SI-BONE news can expect regular updates on quarterly and annual financial results, preliminary revenue announcements, and changes to financial guidance. Recent communications have highlighted double-digit worldwide and U.S. revenue growth, gross margin performance, adjusted EBITDA trends, and cash and cash equivalents. The company also reports operational metrics such as the number of active U.S. physicians using its technologies and revenue per sales territory.
Beyond earnings, SI-BONE’s news flow includes information on reimbursement developments, such as New Technology Add-on Payments and other payment designations for procedures involving products like iFuse TORQ TNT and iFuse Bedrock Granite. The company also issues 8-K-linked press releases covering leadership and board changes, including retirements, consulting agreements, and commercial leadership transitions.
Another recurring theme in SI-BONE news is participation in healthcare and medtech investor conferences hosted by firms such as Piper Sandler, Morgan Stanley, Canaccord Genuity, Truist Securities, and Goldman Sachs. These events often feature fireside chats or presentations where management discusses sacropelvic technologies, clinical evidence, and financial performance, with webcasts made available through the investors section of SI-BONE’s website.
For anyone tracking SIBN, this page offers a centralized view of SI-BONE’s earnings releases, preliminary updates, conference appearances, and other company announcements related to its sacropelvic surgical technology platform.
SI-BONE (Nasdaq: SIBN) reported preliminary, unaudited fourth quarter and full year 2025 results. For Q4 2025 the company expects worldwide revenue of $56.2–$56.3 million (~15% growth) and U.S. revenue of $53.3–$53.4 million (~14% growth). Q4 active U.S. physicians rose to ~1,640 (up 250, ~18%). Cash and cash equivalents were ~$147.7 million, implying net cash generation of ~$2.0 million in the quarter. For fiscal 2025 the company expects worldwide revenue of $200.8–$200.9 million (~20% growth) and U.S. revenue of $190.9–$191.0 million (~21% growth). These figures are preliminary and subject to adjustment pending financial close and audit; final results will be provided on the Q4 2025 earnings call in late February 2026.
SI-BONE (Nasdaq: SIBN) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2, 2025. Management will host a fireside chat at 9:00 a.m. Pacific / 12:00 p.m. Eastern.
Investors can register to listen and access a live audio webcast via the company’s Investors website. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (Nasdaq: SIBN) reported Q3 2025 results with $48.7M worldwide revenue, up 20.6% year-over-year, and $46.4M U.S. revenue, up 21.2%. Gross margin improved to 79.8% (up 75 bps). Net loss narrowed to $4.6M (‑$0.11/share) and adjusted EBITDA was positive $2.3M. The company generated $2.3M of operating cash flow and held $145.7M in cash and equivalents.
Operationally, active U.S. physicians rose 27% to 1,530 and trailing 12-month average revenue per territory grew 16%. Effective Oct 1, 2025, procedures using iFuse TORQ TNT qualify for an NTAP of over $4,100. SI-BONE raised full-year 2025 revenue guidance to $198M–$200M and expects full-year gross margin of ~79.5%.
SI-BONE (Nasdaq: SIBN) reported second-quarter 2025 results with worldwide revenue of $48.6M (+21.7% YoY) and U.S. revenue of $46.4M (+22.8% YoY). Gross margin was 79.8% and adjusted EBITDA turned positive at $1.0M, while net loss improved to $6.2M (‑31.2%). Cash and equivalents totaled $145.5M with $1.1M net cash generated in the quarter. Operationally, active U.S. physicians grew ~25% to 1,440 and trailing 12‑month average revenue per territory rose ~23%. Fiscal 2025 revenue guidance was updated to $195M–$198M (~17%–18% growth) with expected full‑year positive adjusted EBITDA.
SI-BONE (Nasdaq: SIBN) will report its third quarter 2025 financial results after market close on Monday, November 10, 2025.
Management will host a conference call on that day at 1:30 p.m. PT / 4:30 p.m. ET. Investors can register for the live call via the provided media-server link and listen to the live webcast in the Investors section of the company website. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will conduct a fireside chat on September 9, 2025, at 4:00 AM PT / 7:00 AM ET.
Investors can access the presentation through registration, and a live webcast will be available on SI-BONE's investor relations website. The webcast recording will remain accessible for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will conduct a fireside chat on August 12, 2025, at 3:00 PM ET.
Investors can access the presentation through a webcast by registering online, and the live audio will be available on the company's website investor section. The webcast recording will remain accessible for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has scheduled its second quarter 2025 financial results announcement for August 4, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET. Investors can access the call through registration and listen to the live webcast on SI-BONE's investor relations website. The webcast recording will remain available for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami Beach. The company's management will conduct a fireside chat on June 10, 2025, at 8:20 AM PT/11:20 AM ET. Investors can access the live webcast through registration and the company's website. The webcast recording will be available for replay on SI-BONE's investor relations page for at least 90 days following the event.
FAQ
What is the current stock price of Si-Bone (SIBN)?
What is the market cap of Si-Bone (SIBN)?
